The news: The FDA approved AstraZeneca’s nasal spray influenza vaccine, FluMist, for administration at home.

• As the first of its kind, FluMist is approved to be self-administered by adults up to 49 years of age or administered by a parent or caregiver to individuals between the ages of 2 and 17.
• AstraZeneca anticipates FluMist will be available for the 2025-2026 flu season.

Here’s how it works: Once available, adults can have FluMist delivered directly to their homes through a service dubbed FluMist Home.